Seer (SEER) Net Income towards Common Stockholders (2020 - 2026)

Seer (SEER) recorded quarterly Net Income towards Common Stockholders of -$16.8 million in Q1 2026, down 5.27% quarter-over-quarter from -$16.0 million in Q4 2025, and up 15.6% on a YoY basis from -$14.6 million in Q1 2025.

Seer (SEER) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

Seer's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$16.8 million for Q1 2026.

  • In Q1 2026, Net Income towards Common Stockholders rose 15.6% year-over-year to -$16.8 million; the TTM figure through Mar 2026 stood at -$70.5 million (up 18.15% YoY), while the FY2025 annual figure was -$73.6 million, up 15.25% from the prior year.
  • Net Income towards Common Stockholders was -$16.8 million for Q1 2026 at Seer, down from -$16.0 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $67.5 million in Q4 2023 to a low of -$24.0 million in Q3 2022.
  • Historically, Net Income towards Common Stockholders has averaged -$16.0 million across 5 years, with a median of -$21.3 million in 2024.
  • The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders soared 399.87% in 2023, then tumbled 132.56% in 2024.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$22.5 million in 2022, then jumped by 399.87% to $67.5 million in 2023, then slumped by 132.56% to -$22.0 million in 2024, then climbed by 27.27% to -$16.0 million in 2025, then dropped by 5.27% to -$16.8 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$16.8 million (Q1 2026), -$16.0 million (Q4 2025), and -$18.2 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Alterity Therapeutics 719,706.53 Bn 719,706.50 Bn - -
2 Belite Bio 55,800.00 Bn 55,800.00 Bn - -26.94 Mn
3 Quantum Biopharma 18,182.30 Bn 18,182.29 Bn - -13.56 Mn
4 Legend Biotech 3,154.00 Bn 3,153.71 Bn 242.10 Mn 2.50 Mn
5 Akari Therapeutics 1,844.30 Bn 1,844.29 Bn - -14.46 Mn
6 Evaxion A 1,567.96 Bn 1,567.94 Bn - -3.63 Mn
7 Psyence Biomedical 251.43 Bn 251.42 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 112.56 Bn 105.31 Bn 2.59 Bn 1.03 Bn
9 Abivax 94.37 Bn 94.37 Bn - -56.48 Mn
10 Seer 99.67 Mn 99.67 Mn 982,000.00 -16.84 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -16.84 Mn
Dec 31, 2025 -15.99 Mn
Sep 30, 2025 -18.23 Mn
Jun 30, 2025 -19.42 Mn
Mar 31, 2025 -19.95 Mn
Dec 31, 2024 -21.99 Mn
Sep 30, 2024 -21.33 Mn
Jun 30, 2024 -22.85 Mn
Mar 31, 2024 -20.68 Mn
Dec 31, 2023 67.55 Mn
Sep 30, 2023 -21.09 Mn
Jun 30, 2023 -23.43 Mn
Mar 31, 2023 -23.96 Mn
Dec 31, 2022 -22.53 Mn
Sep 30, 2022 -23.98 Mn
Jun 30, 2022 -22.82 Mn
Mar 31, 2022 -23.65 Mn
Dec 31, 2021 -19.74 Mn
Sep 30, 2021 -18.39 Mn
Jun 30, 2021 -16.62 Mn